We expected the novel T22-GFP-H6-Auristatin NC to selectively deliver Auristatin E to cycling and quiescent CXCR4+ LSCs target cells achieving a potent inhibition of AML dissemination in the absence of toxicity, because of its low uptake in normal tissues, as we reported for a NC loaded with a CRC sensitive drug [22]. Here, CXCR4 is linked to acute myeloid leukemia.